John Parkinson

The investigational vaccine, mRNA-1345, developed for seniors has its FDA PDUFA date in a few days.

In patients with Clostridium difficile infection (CDI), ibezapolstat was shown to have similar results to a standard of care therapy.

New data from a World Health Organization (WHO) repository illustrates the treatment challenges during the acute phase of the pandemic.

According to the latest Centers for Disease Control and Prevention (CDC) data, these strains have increased in incidence rates, and now account for nearly a third of all US cases.

Hospital grades released by Leapfrog reviews state and now metro areas for safety and patient satisfaction.

In a new real-world study, Sanofi and AstraZeneca’s nirsevimab-alip (Beyfortus) demonstrated high efficacy against respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD).

A Centers for Disease Control and Prevention (CDC) investigator offers insights into their investigation of customers receiving vampire facials (a spa cosmetic procedure) and contracting the virus afterwards.

This cephalosporin antibiotic was examined against colistin-susceptible gram-negative infections.

A large study being presented at ESCMID shows the therapy was associated with a significantly lower mortality at 14-days and 28-days.

A novel approach using this emerging technology looks to interfere with antibiotic resistance expression and reduce this global health issue.

A study finds that despite the development of some new agents for highly-resistant pathogens, prescribers are reluctant to utilize these therapies.

New data reinforced the safety and tolerability profile of this antiretroviral therapy for this patient population who are virologically suppressed.

Pivmecillinam (Pivya) was given the nod from the federal agency, and is indicated for female adults with uncomplicated urinary tract infections (UTIs) caused by susceptible isolates of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus.

RedHill Biopharma said it has enrolled its first participant for the study examining the investigational therapy, RHB-107 (upamostat).

With this approval, aztreonam-avibactam becomes the first β-lactam/β-lactamase inhibitor antibiotic combination approved in the European Union for treating multidrug-resistant infections, including metallo-β-lactamase-producing bacteria.

US Department of Agriculture’s Food Safety and Inspection Service (FSIS) issued a public health alert over the meat.

The vaccine’s developer, YS Biopharma, will begin its phase 1 clinical trial in the Philippines this summer.

The streptococcal pneumoniae urine antigen (SPUA) test was studied over the course of a year to determine if it provided any benefits in terms of diagnostic capability or aided in reducing empirical antibiotic use.

A large cohort study found this patient group more susceptible to repeat admissions, and points to potential issues associated with ambulatory care.

In these patient encounters, a deep cough as a symptom raised concerns around pneumonia and may have prompted prescription of antimicrobials, but did not show a resolution of symptoms sooner.

The company’s investigational ABCWY vaccine candidate will be reviewed by the FDA by February 14, 2025.

A small study found physical health problems lingered 1 year after their hospital stay.

In a new federal survey, as many as 3 in 10 US adults have had the condition at some point.

This annual event hosted by The Peggy Lillis Foundation (PLF) released their full agenda for advocacy and education that will be happen next week in Washington DC.

The origins of the recent H5N1 (avian flu) case in Texas remain unknown, but a researcher offers insights into transmission between animals and humans, the likelihood of more cases, vaccine availability, and treatment.

The company is going to submit their data to the FDA to seek approval for people within this age group.

The federal agency has given the nod for dolutegravir/lamivudine (Dovato) for teens living with the virus and offers a novel option for patients.

As a potential alternative to antibiotic treatments, this investigational immunization offered protection for several years.

The case involves a man who had contact with wild monkeys.

During the 2014-2016 African epidemic, investigational Ebola vaccines demonstrated safety and immunogenicity.